2C-T-35
2C-T-35, also known as 2C-T-DFM or as 4-difluoromethylthio-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
2C-T-35, also known as 2C-T-DFM or as 4-difluoromethylthio-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a potent agonist at the serotonin receptor 5-HT 2A in vitro, with a binding affinity (K i ) of 6.3 nM.
In animal studies, 2C-T-DFM was the most effective compound at producing a head-twitch response out of a series of related analogues, with an average of 33 head-twitches per 10 minutes compared to 21 for 2C-T-TFM. While it had previously been proposed as a theoretical compound, 2C-T-35 is not known to have been tested in humans.
It is a controlled substance in Canada under phenethylamine blanket-ban language.
2C-T-35, also known as 2C-T-DFM or as 4-difluoromethylthio-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a potent agonist at the serotonin receptor 5-HT 2A in vitro, with a binding affinity (K i ) of 6.3 nM.
In animal studies, 2C-T-DFM was the most effective compound at producing a head-twitch response out of a series of related analogues, with an average of 33 head-twitches per 10 minutes compared to 21 for 2C-T-TFM. While it had previously been proposed as a theoretical compound, 2C-T-35 is not known to have been tested in humans.
It is a controlled substance in Canada under phenethylamine blanket-ban language.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371212432 under CC BY-SA 4.0; modifications have been made.